Drug firm Zydus Healthcare on Sunday said it has launched generic anti-diabetic Dapagliflozin tablets across the country under the brand name ‘Dapaglyn’ at highly affordable price to increase patient access.
The company has launched its Dapagliflozin tablets in the strengths of 10 mg and 5 mg priced at ₹17 and ₹14, respectively, in India upon patent expiry of the product, Zydus Healthcare said in a statement.
“In keeping with its efforts to make therapies accessible and affordable to patients, the drug will be highly economical, priced at 1/3rd the cost than currently available Dapagliflozin brands in India,” it added.
The once-daily tablets are indicated as an adjunct to diet and exercise, and aim to improve glycemic control in adults with Type 2 diabetes mellitus, Zydus Healthcare said.
Dapagliflozin is part of a newer class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors, it added.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.